McAdams Wright Ragen Upgrades Dendreon (DNDN) to Hold
More News related to DNDN
- Dendreon (DNDN) volatility of 65 near two-year lows
- Dendreon (DNDN) Completes Submission of Amended Biologics License Application for PROVENGE®
- Dendreon (DNDN) Completes Submission of Biologics License Application for PROVENGE
- Dendreon Completes Submission of Biologics License Application for PROVENGE
- Dendreon to Hold Conference Call on Wednesday, November 11, 2009 at 4:30 PM ET
More News related to Upgrades
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Unusual 11 Mid-Day Movers 11/09: EONC, EWBC, REV, PRST Higher; GTN, CHNG, SRZ, CHDX Lower
- Notable Analyst Rating Changes: RSH, ANF, NOC, ADBE, HERO Upgraded; RIMM, RHT, GPS, AZN, SGY Downgraded
- Morning Movers 11/09: EWBC, CVM, REV, CGEN, RSH Higher; CHDX, SRZ, GTN, RPRX, VSR Lower
- Notable Mergers and Acquisitions of the Day 11/9: ERTS, GE/CMCSA, EWBC
McAdams Wright Ragen upgrades Dendreon (Nasdaq: DNDN) from Sell to Hold.
For more analyst ratings on DNDN click here.
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients.
Related Categories
UpgradesStocks Mentioned
+0.61Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
